BioSpace News Archive

Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that it will participate virtually in two upcoming conferences in October: TCR-based Therapies Summit Title: ARTEMIS ® Antibody TCR T Cell Therapies for Solid Tumors Speaker: Cheng Liu, Ph.D., President and CEO Date: Tuesday, October 27, 2020 Time: 9:00 a.m

Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Michael D. Harvey, PhD as Senior Vice President, Drug Development. In his position, Dr. Michael Harvey will be responsible for overseeing all R&D activities pertaining to CMC, nonclinical development, and regulatory affairs. “As we grow our operations, I am pleased to welcome Michael to our leader

Foundation to Fight H-ABC, a non-profit organization dedicated to increasing awareness and driving development of a cure for the degenerative children’s disease, H-ABC, today announced a sponsored research agreement with the University of Massachusetts Medical School and Yale University to advance a targeted gene therapy for H-

Voycare, Inc., a telemedicine service provider and global Chinese language digital health platform exclusively dedicated to women’s health, is pleased to announce it has officially launched its client portal after completing closed beta testing last month.

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced positive topline data from an interim analysis of its Phase 2 clinical trial of imsidolimab

Bioclinica, an integrated solutions provider of clinical life science and technology expertise, delivering powerful insight into clinical trial development in bringing new therapies to people worldwide, announced that Robert R. Ford, MD, will join the staff as Senior Advisor, Chief Medical Officer Emeritus.

SK Biopharmaceuticals and Ono Pharmaceutical announced that they have entered into an exclusive licensing agreement for Ono to develop and commercialize cenobamate in Japan. Cenobamate is a treatment for partial-onset seizures (POS) that received FDA approval in 2019.

CEFALY Technology today announced that the U.S. Food and Drug Administration (FDA) has cleared the CEFALY DUAL medical device as an over-the-counter (OTC) product

Cansortium Inc. (“Cansortium” or the “Company”) (CSE: TIUM.U), (OTCQB: CNTMF), a vertically-integrated provider of premium-quality medical Cannabis operating under the Fluent™ brand, today announced that it has received approval from the Florida Department of Health and will commence sales of edibles today in each of its Fluent dispensaries in the state.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, and Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research, today announced encouraging preliminary results from an ongoing Phase 1 clinical study of VAC2 in non-small cell lung cancer (NSCLC).